Tvardi Therapeutics (TVRD) Stock Price, Quote, News & History | Benzinga

SPY774.73−0.56%QQQ754.88−0.63%BTC/USD83,312.11−2.61%DIA509.03−1.07%GLD375.94−1.66%TLT76.87−0.53%

Tvardi Therapeutics Inc (TVRD) Stock Price, Quote, News & History

TVRDNASDAQ

Trade with Public

Trade with Public

$1.10

0.021.85%

Last update: Oct 7, 9:28 AM

$1.10

0.021.85%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$1.08

Close

-

Volume / Avg.

68.59K / 2.19M

Day Range

$1.04 - $1.11

52 Wk Range

0.93 - 43.65

Market Cap

$14.67M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

28

Short Interest

1.92%

Days to Cover

2.29

Recent Tvardi Therapeutics, Inc. News

Why Is Tvardi Therapeutics Stock Falling Thursday?

Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.

Vandana Singh

Why Is Tvardi Therapeutics Stock Gaining Tuesday?

Tvardi Therapeutics (TVRD) stock jumps 50% after reporting positive Phase 1 data for its next-gen STAT3 inhibitor, TTI-109. Read more.

Vandana Singh

Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarket

Universe Pharmaceuticals Inc (NASDAQ: UPC) surged 228.4% to $9.72 in pre-market trading after announcing acquisition of Best Praise International for $10.75 million.

Avi Kapoor

This Cerebras Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday

Top Wall Street analysts changed their outlook on top names. See upgrades, downgrades & initiations on analyst ratings page. Analysts think CBRS stock is a buy.

Avi Kapoor

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-25.03M

Investing Cash Flow (TTM)

20.47M

Financing Cash Flow (TTM)

-321.00K

Free Cash Flow (TTM)

-25.03M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-4.88M

Analyst Trends and Forecast

1

Apr

1

Jun

3

Jul

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$1.15M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.73

Earnings Yield % (TTM)

-264.52%

Earnings Yield % (FWD)

-353.46%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.63

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$15.77M

Debt to Equity

0.02

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-